Mandate

Vinge advises NOTE in connection with the company’s underwritten rights issue

March 11, 2010

Vinge is advising NOTE AB (publ) in connection with the new issue of shares for approximately SEK 87 million with pre-emption rights for NOTE’s shareholders. The rights issue is conditional upon approval by the members at an extraordinary general meeting to be held on 7 April 2010. The new issue is fully underwritten by a subscription agreement and guarantee commitment by NOTE’s major shareholders.

NOTE is listed on NASDAQ OMX Stockholm. Note’s business concept is to provide electronics manufacturing and logistics services.

Vinge’s team consisted of Ola Sandersson, Dain Nevonen and Christian Granqvist. Bo Adrianzon is the responsible partner.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024